Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B
Open Access
- 22 January 2025
- journal article
- research article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 60 (4) , 469-478
Abstract
Background: Hepatitis B virus (HBV) RNA is an important serum biomarker of hepatic covalently closed circular DNA (cccDNA) transcriptional activity; however, its clinical characteristics remain unclear. This study evaluated the clinical utility of HBV RNA levels in patients with chronic hepatitis B (CHB). Methods: We studied 87 CHB patients with serum HBV DNA levels ≥ 5.0 log IU/mL who initiated entecavir (ETV) treatment between 2000 and 2018. Serum HBV RNA levels were measured at three-time points: before ETV treatment, at 12 weeks, and at 48 weeks after starting ETV treatment. Clinical markers associated with the antiviral effects of ETV treatment were analyzed. Results: Serum HBV RNA levels decreased in both HBeAg-positive and -negative patients during the observation period. In HBeAg-positive patients, multivariable analysis showed that lower HBV RNA levels at 48 weeks of ETV treatment were independently associated with HBeAg seroconversion. Additionally, lower baseline HBV RNA levels significantly predicted virologic response in those patients. In contrast, among HBeAg-negative patients, lower HBV core-related antigen (HBcrAg) levels and the FIB-4 index were independently associated with virologic response. In HBeAg-positive patients, those with higher baseline HBV RNA levels showed a more significant reduction in hepatitis B surface antigen levels. Conclusion: Serum HBV RNA levels predicted HBeAg seroconversion and early HBV DNA reduction in HBeAg-positive patients, while HBcrAg was significantly associated with virologic response in HBeAg-negative patients. These findings highlight the different predictive roles of HBV RNA and HBcrAg based on HBeAg status, which may provide individualized treatment strategies.Keywords
Funding Information
- KAKENHI (JP21K16000, JP21K08006)
- AMED (23fk0210083s0403)
- Hiroshima University
This publication has 36 references indexed in Scilit:
- HBV‐RNA Co‐amplification May Influence HBV DNA Viral Load DeterminationHepatology Communications, 2020
- Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus InfectionHepatology, 2018
- Chronic Hepatitis B InfectionJAMA, 2018
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology, 2018
- Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patientsJournal of Gastroenterology, 2013
- Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine†Hepatology, 2007
- Increased risk of adefovir resistance in patients with lamivudine‐resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy†Hepatology, 2006
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapyJournal of Medical Virology, 2003
- Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC)Seminars in Cancer Biology, 2000